Monoclonal antibodies as tumor targeting agents in multiplemyeloma

Multiple myeloma (MM) is a hematological malignancy that remains incurable becausemost patients will eventually relapse or become refractory to the treatments. Novel agentsare currently in development for the treatment of relapsed/refractory MM, includingimmunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, cell signalingtargeted therapies, and strategies targeting the tumor microenvironment. for this purposethe conformational structure of the hexapeptide H3N+-FDDARL-COO-, H3N+-FVDVRLCOO-, H3N+-FSDARL-COO- has been investigated by the PCILO method. Thecomputational results show this tree structure have no functionality group for bind to Mprotein. Moreover, H3N+-FVDVRL-COO- has assumes the somewhat amphipathicstructure

Keywords:

Monocolonal antibodies , targeting peptide , multiple myeloma , conformational study